Both GLP-2 and GIP reduce the bone resorption (measured as CTX) in healthy persons. In this study, we will investigate wether GLP-2 and GIP is reducing CTX in persons with type 2 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
10
Hvidovre University Hospital
Hvidovre, Denmark
CTX
Bone resorption measured as collagen type 1 C-terminal telopeptide (CTX) in serum.
Time frame: -10 minutes to 240 minutes
P1NP
Bone formation measured as procollagen type 1 N-terminal propeptide (P1NP) in serum.
Time frame: -10 minutes to 240 minutes
PTH
PTH measured in serum
Time frame: -10 minutes to 240 minutes
Sclerostin
Bone marker.
Time frame: -10 min to 240 min.
Glucose
Measured in serum
Time frame: -10 minutes to 240 minutes
Insulin
Measured in serum
Time frame: -10 minutes to 240 minutes
C-peptide
Measured in serum
Time frame: -10 minutes to 240 minutes
GIP
Glucose-dependent insulinotropic polypeptide measured in plasma.
Time frame: -10 minutes to 240 minutes
GLP-2
Glucagon-like peptide 2 measured in plasma.
Time frame: -10 minutes to 240 minutes
Glucagon
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Glucagon measured in plasma
Time frame: -10 minutes to 240 minutes
Blood pressure
Measured before blood sampling
Time frame: -10 minutes to 240 minutes
Heart rate
Measured before blood sampling
Time frame: -10 minutes to 240 minutes